Iterum Therapeutics receives Nasdaq delisting determination for non-compliance with stockholders' equity requirement

Iterum Therapeutics plc

Nasdaq notified Iterum on Oct 1, 2024 that it failed to meet terms of extension to comply with minimum $2.5M stockholders' equity requirement.
Company intends to request a hearing before Nasdaq Hearings Panel; delisting stayed pending hearing conclusion.
At hearing, Iterum will present a plan to regain compliance; Panel may grant extension up to March 31, 2025.
Ordinary shares continue trading on Nasdaq Capital Market under symbol ITRM pending hearing process outcome.
No assurance that Panel will grant extension or that company will ultimately regain compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.